» Articles » PMID: 36397054

Structural Tissue Damage and 24-month Progression of Semi-quantitative MRI Biomarkers of Knee Osteoarthritis in the IMI-APPROACH Cohort

Abstract

Background: The IMI-APPROACH cohort is an exploratory, 5-centre, 2-year prospective follow-up study of knee osteoarthritis (OA). Aim was to describe baseline multi-tissue semiquantitative MRI evaluation of index knees and to describe change for different MRI features based on number of subregion-approaches and change in maximum grades over a 24-month period.

Methods: MRIs were acquired using 1.5 T or 3 T MRI systems and assessed using the semi-quantitative MRI OA Knee Scoring (MOAKS) system. MRIs were read at baseline and 24-months for cartilage damage, bone marrow lesions (BML), osteophytes, meniscal damage and extrusion, and Hoffa- and effusion-synovitis. In descriptive fashion, the frequencies of MRI features at baseline and change in these imaging biomarkers over time are presented for the entire sample in a subregional and maximum score approach for most features. Differences between knees without and with structural radiographic (R) OA are analyzed in addition.

Results: Two hundred eighty-nine participants had readable baseline MRI examinations. Mean age was 66.6 ± 7.1 years and participants had a mean BMI of 28.1 ± 5.3 kg/m. The majority (55.3%) of included knees had radiographic OA. Any change in total cartilage MOAKS score was observed in 53.1% considering full-grade changes only, and in 73.9% including full-grade and within-grade changes. Any medial cartilage progression was seen in 23.9% and any lateral progression on 22.1%. While for the medial and lateral compartments numbers of subregions with improvement and worsening of BMLs were very similar, for the PFJ more improvement was observed compared to worsening (15.5% vs. 9.0%). Including within grade changes, the number of knees showing BML worsening increased from 42.2% to 55.6%. While for some features 24-months change was rare, frequency of change was much more common in knees with vs. without ROA (e.g. worsening of total MOAKS score cartilage in 68.4% of ROA knees vs. 36.7% of no-ROA knees, and 60.7% vs. 21.8% for an increase in maximum BML score per knee).

Conclusions: A wide range of MRI-detected structural pathologies was present in the IMI-APPROACH cohort. Baseline prevalence and change of features was substantially more common in the ROA subgroup compared to the knees without ROA.

Trial Registration: Clinicaltrials.gov identification: NCT03883568.

Citing Articles

Exercise and footwear in medial knee osteoarthritis: a randomized controlled trial comparing flat flexible footwear to stable supportive shoes.

Dainese P, Stautemas J, De Mits S, Wittoek R, Van Ginckel A, Huysse W Rheumatol Adv Pract. 2024; 8(4):rkae133.

PMID: 39669115 PMC: 11637601. DOI: 10.1093/rap/rkae133.


Risk factors for early onset patellofemoral osteoarthritis following anterior cruciate ligament reconstruction with hamstring tendon autograft.

Li B, Qian Y, Liu F, Xu B J Orthop Surg Res. 2024; 19(1):708.

PMID: 39487515 PMC: 11531109. DOI: 10.1186/s13018-024-05205-w.


Fluctuation of Bone Marrow Lesions and Inflammatory MRI Markers over 2 Years and Concurrent Associations with Quantitative Cartilage Loss.

Roemer F, Jansen M, Maschek S, Mastbergen S, Marijnissen A, Wisser A Cartilage. 2024; :19476035241287694.

PMID: 39460605 PMC: 11556660. DOI: 10.1177/19476035241287694.


Artificial intelligence in knee osteoarthritis: A comprehensive review for 2022.

Cigdem O, Deniz C Osteoarthr Imaging. 2024; 3(3).

PMID: 38948116 PMC: 11213283. DOI: 10.1016/j.ostima.2023.100161.


Approaches to optimize analyses of multidimensional ordinal MRI data in osteoarthritis research: A perspective.

Collins J, Roemer F, Guermazi A Osteoarthr Cartil Open. 2024; 6(2):100465.

PMID: 38601258 PMC: 11004399. DOI: 10.1016/j.ocarto.2024.100465.

References
1.
Roemer F, Kwoh C, Hannon M, Hunter D, Eckstein F, Fujii T . What comes first? Multitissue involvement leading to radiographic osteoarthritis: magnetic resonance imaging-based trajectory analysis over four years in the osteoarthritis initiative. Arthritis Rheumatol. 2015; 67(8):2085-96. PMC: 4519416. DOI: 10.1002/art.39176. View

2.
Lohmander L, Hellot S, Dreher D, Krantz E, Kruger D, Guermazi A . Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014; 66(7):1820-31. DOI: 10.1002/art.38614. View

3.
van Helvoort E, van Spil W, Jansen M, Welsing P, Kloppenburg M, Loef M . Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and.... BMJ Open. 2020; 10(7):e035101. PMC: 7389775. DOI: 10.1136/bmjopen-2019-035101. View

4.
Hunter D, Schofield D, Callander E . The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014; 10(7):437-41. DOI: 10.1038/nrrheum.2014.44. View

5.
Oo W, Yu S, Daniel M, Hunter D . Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs. 2018; 23(4):331-347. DOI: 10.1080/14728214.2018.1547706. View